marzeptacog alfa (activated)

Marzeptacog alfa (activated) is a recombinant, activated human factor VIIa variant engineered for increased catalytic activity and improved pharmacokinetics compared to wild-type rFVIIa. It is designed for subcutaneous administration, offering greater convenience over intravenous therapies. The drug acts as a replacement therapy to promote hemostasis by activating the coagulation cascade via factor X activation. Developed primarily for the treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B who have inhibitors, it has also been studied in other rare bleeding disorders. Marzeptacog alfa (activated) demonstrates increased bioavailability, prolonged half-life, and enhanced therapeutic activity following subcutaneous injection[1][4][6].

Brand names

MarzAA

Other names

marzeptacog alpha